Johnson & Johnson (NYSE:JNJ) is Rothschild & Co. Asset Management US Inc.’s 5th Largest Position

Share on StockTwits

Rothschild & Co. Asset Management US Inc. lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 22.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 453,356 shares of the company’s stock after selling 131,776 shares during the quarter. Johnson & Johnson accounts for 1.2% of Rothschild & Co. Asset Management US Inc.’s portfolio, making the stock its 5th biggest holding. Rothschild & Co. Asset Management US Inc.’s holdings in Johnson & Johnson were worth $67,495,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Newfound Research LLC bought a new stake in Johnson & Johnson during the 3rd quarter valued at $28,000. Islay Capital Management LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at $42,000. FAI Wealth Management raised its position in Johnson & Johnson by 45.9% during the 2nd quarter. FAI Wealth Management now owns 321 shares of the company’s stock valued at $45,000 after purchasing an additional 101 shares in the last quarter. SeaBridge Investment Advisors LLC raised its position in Johnson & Johnson by 160.0% during the 2nd quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock valued at $46,000 after purchasing an additional 200 shares in the last quarter. Finally, HWG Holdings LP bought a new stake in Johnson & Johnson during the 2nd quarter valued at $49,000. Institutional investors own 67.44% of the company’s stock.

In other news, EVP Kathryn E. Wengel sold 16,115 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the sale, the executive vice president now owns 66,658 shares in the company, valued at $10,233,336.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.27% of the stock is currently owned by insiders.

Johnson & Johnson stock opened at $146.36 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.24 and a current ratio of 1.48. The business’s 50-day simple moving average is $145.51 and its two-hundred day simple moving average is $146.57. The company has a market cap of $385.30 billion, a PE ratio of 23.01, a PEG ratio of 3.04 and a beta of 0.69. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.98 by $0.22. The business had revenue of $21.08 billion for the quarter, compared to the consensus estimate of $20.15 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The company’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.12 EPS. As a group, analysts predict that Johnson & Johnson will post 7.99 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a dividend of $1.01 per share. The ex-dividend date is Monday, November 23rd. This represents a $4.04 annualized dividend and a yield of 2.76%. Johnson & Johnson’s payout ratio is presently 46.54%.

Several research firms have recently commented on JNJ. ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Monday, August 3rd. Raymond James reissued a “buy” rating on shares of Johnson & Johnson in a research report on Friday. Cantor Fitzgerald boosted their price target on Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 14th. Stifel Nicolaus lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Finally, Credit Suisse Group boosted their price target on Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 14th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $164.93.

Johnson & Johnson Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Article: What are momentum indicators and what do they show?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MEMBERS Trust Co Raises Stock Holdings in Johnson & Johnson
MEMBERS Trust Co Raises Stock Holdings in Johnson & Johnson
The Manufacturers Life Insurance Company Acquires 24,826 Shares of American Water Works Company, Inc.
The Manufacturers Life Insurance Company Acquires 24,826 Shares of American Water Works Company, Inc.
Johnson & Johnson  Position Lifted by Edge Capital Group LLC
Johnson & Johnson Position Lifted by Edge Capital Group LLC
Johnson & Johnson  Position Boosted by OPSEU Pension Plan Trust Fund
Johnson & Johnson Position Boosted by OPSEU Pension Plan Trust Fund
Acadian Asset Management LLC Boosts Stake in The Walt Disney Company
Acadian Asset Management LLC Boosts Stake in The Walt Disney Company
Jaffetilchin Investment Partners LLC Purchases 670 Shares of Johnson & Johnson
Jaffetilchin Investment Partners LLC Purchases 670 Shares of Johnson & Johnson


 
© 2006-2020 Zolmax.